Loading...
Symbols:
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
Transcripts
- National Semiconductor Corporation F1Q09 (Qtr End 08/24/08) Earnings Call Transcript
- Aceto Corporation F4Q08 (Qtr End 06/30/08) Earnings Call Transcript
- Logility, Inc. F1Q09 (Qtr End 07/31/08) Earnings Call Transcript
- Smith Micro Software, Inc. Q2 2008 Earnings Call Transcript
- BioForm Medical, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript
- Sycamore Networks, Inc. F4Q08 (Qtr End 07/31/08) Earnings Call Transcript
- Alliance Imaging, Inc. Q2 2008 Earnings Call Transcript
- Somaxon Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
- Volcano Corporation Q2 2008 Earnings Call Transcript
- ABM Industries Incorporated F3Q08 (Qtr End 07/31/08) Earnings Call Transcript
-
Editor's Picks
-
Most Popular
- GSEs Into Conservatorship: Can Housing Stabilize Now?
- A Closer Look at the Treasury's GSE Preferred Stock Purchase Plan
- Buying Berkshire: The Ultimate No-Brainer
- PowerShares Dynamic Retail ETF Finds Bargains in Discount Retailers
- Global Stock Markets: We All Fall Down!
- American Capital Agency: Making Money the Old-Fashioned Way
- Full list of Editor's Picks »
- Wall Street Breakfast: Must-Know News »
- Apple: Steve and I Have Been Wrong »
- Gold Futures' Dirty Secret (Part II) »
- Rescuing Frannie »
- Why Commodities May Be Nearing a Turning Point »
- Is Gold Getting Ready to Bounce? »
- Corning: Looking Very Cheap »
- Friday Outlook: What Phony Sell-off?! »
- Bill Ackman's Letter to Paulson On Restructuring Plan »
- The $64 Trillion Question: What's the Dollar Really Worth? »
- Don't Believe the Gold Bears' Hype »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
yoy
1 Comment
Amgen Looking Attractive Heading into Earnings [view article]
Amgen's has come way too far too fast over the past month (about 25%)......and it was on virtually no news at all. Yet, the same problems that have dogged the company from the FDA since Janurary 2007 continue to exist today. Yes, they've met the (FDA induced) reduced revenues with reduced expenses by closing facilities and reducing personnel but their near term pipeline is still dismal. Everyone seems to be pinning their hopes on Denosumab and that it will blow away expectations. If Denosumab fails to deliver the expected grand slam, look out below. Denosumab is the only important late stage product left in Amgen's pipeline. I'd say this is a "buy the rumor, sell the fact" situation so any profits should be banked here and then take a wait and see approach. Jul 23 09:47 PM